Cancer peptides combined with GM-CSF for breast cancer treatment
A Phase I Study of Cancer Peptides Plus GM-CSF and Adjuvant Following Completion of Prescribed Systemic Therapy of Estrogen Receptor Positive Breast Cancer
This study is testing a new vaccine combined with a booster to see if it can safely help the immune system fight estrogen receptor-positive breast cancer.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 18 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Duke University Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy, radiation |
| Locations | 1 site (Durham, North Carolina) |
| Trial ID | NCT04270149 on ClinicalTrials.gov |
What this trial studies
This phase I study evaluates the safety of a peptide vaccine derived from estrogen receptors in patients with estrogen receptor-positive breast cancer. The vaccine is combined with an adjuvant and GM-CSF to enhance the immune response. The primary goal is to assess the safety of this treatment, while the secondary goal focuses on measuring the immune response generated by the vaccine. This approach aims to improve outcomes for patients with endocrine-resistant breast cancer.
Who should consider this trial
Good fit: Ideal candidates include adults with resected, estrogen receptor-positive breast cancer who have completed standard chemotherapy and meet specific health criteria.
Not a fit: Patients with non-estrogen receptor-positive breast cancer or those who have not completed standard chemotherapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a new immunotherapy option for patients with difficult-to-treat breast cancer.
How similar studies have performed: Other studies have shown promise with peptide vaccines in cancer treatment, but this specific combination is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with histologically confirmed, resected, breast cancer with one of the following characteristics: pT3 or greater T stage with any N stage and M0 pTxN+M0 (i.e., N1,2 or 3) * HLA A0201+ and tumor is ER+ * Patients must have completed any standard chemotherapy recommended by their physician. There must be at least 4 weeks from their last dose of chemotherapy (or surgery if no chemotherapy was given) prior to the first dose of study vaccine. There should be no more than 5 years from the time of completion of any chemotherapy, surgery or HER2 targeted therapy. Ongoing endocrine therapies are permitted as long as they have been administered for at least 3 months prior to study enrollment. * Age ≥ 18 years. * Heme: WBC ≥ 3000/microliter, hemoglobin ≥ 9 g/dL, platelets ≥ 80,000/microliter. * Adequate, renal and hepatic function with serum creatinine \< 1.5 mg/dL, bilirubin \< 1.5 mg/dL (except a bilirubin of \<2.0 will be permitted for patents with Gilbert's syndrome), SGOT/SGPT \< 2 x upper limit of normal. * Ability to understand and provide signed informed consent that fulfills Institutional Review Board's guidelines. Exclusion Criteria: * Subjects with concurrent chemotherapy, radiation therapy, or immunotherapy are excluded. There must be at least 4 weeks between these prior therapy and study treatment. Subjects must have recovered from all acute toxicities from prior treatment. Peripheral neuropathy grade 1 due to prior therapy will be permitted. * Subjects may not have history of distant metastases. * Subjects with a history of autoimmune disease, such as but not restricted to, inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis, scleroderma, or multiple sclerosis. A positive ANA (anti-nuclear antibody) test without other evidence of autoimmune disease will not exclude a subject for this study. A prior history of autoimmune hypothyroidism will not exclude a subject. * Subjects with serious intercurrent chronic or acute illness, such as cardiac disease, (NYHA class III or IV), hepatic disease, or other illness considered by the Principal Investigator as unwarranted high risk for investigational drug treatment. * Subjects with a medical or psychological impediment to probable compliance with the * Concurrent (or within the last 5 years) second malignancy other than non-melanoma skin cancer, cervical carcinoma in situ, controlled carcinoma in situ of the cervix, or controlled superficial bladder cancer. * Presence of an active acute or chronic infection including: an urinary tract infection, HIV (as determined by ELISA and confirmed by Western Blot) or viral hepatitis (as determined by HBsAg and Hepatitis C serology). Subjects with HIV are excluded based on immuno-suppression, which may render them unable to respond to the vaccine; subjects with chronic hepatitis are excluded because of concern that hepatitis could be exacerbated by the injections. * Subjects on steroid therapy (or other immuno-suppressives, such as azathioprine or cyclosporin A) are excluded on the basis of potential immune suppression. Subjects must have had 6 weeks of discontinuation of any steroid therapy (except that used as pre-medication for chemotherapy or contrast-enhanced studies) prior to enrollment. * Subjects with allergies to any component of the vaccine * Pregnant or nursing mothers. * Subjects with acute or chronic skin disorders that will interfere with peptide injection into the skin of the extremities or subsequent assessment of potential skin reactions will be excluded. * Splenectomy
Where this trial is running
Durham, North Carolina
- Duke University Medical Center — Durham, North Carolina, United States (Recruiting)
Study contacts
- Study coordinator: Amy Hobeika, PhD
- Email: AMY.HOBEIKA@DUKE.EDU
- Phone: 919 684 6112
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.